initi coverag focu oncolog stock
messag initi coverag stock assum coverag anoth total launch
stock bullish outlook sector long-term expect continu growth coverag focus
oncolog therapeut categori think repres attract invest theme within therapeut group
top pick arri key catalyst approach addit stock rate buy
bgne tsro adap stock rate neutral loxo
believ sector well-posit bullish outlook long-term addit continu
domest growth bio/pharmaceut therapeut market expect emerg market china becom import
addit sourc growth innov view remain key driver stock expect suppli
new drug treatment modal remain strong new drug approv track new high level
public compani acquisit investor expect follow tax reform public compani
transact announc ytd view activ sector pois increas sever key drug franchis face loss
patent protect biosimilar launch loom balanc sheet potenti acquir remain strong continu channel
consolid cost manag program repres potenti sourc uncertainti think innov compani
remain well posit context dynam
coverag focus oncolog therapeut categori repres attract invest theme view
oncolog constitut second biggest therapeut market us grow annual significantli faster drug
expect oncolog product demand continu increas driven unmet medic need new drug remain
high cancer mortal rate decreas increment recent year simultan oncology-focus compani
investor benefit uniqu dynam categori rel therapeut area includ acceler
develop multi-ind drug develop combin therapi oncology-focus compani also oper
one least generic pharmaceut market us combin high degre fragment type
cancer could make categori potenti less expos commerci headwind result believ oncolog seen
larger amount resourc alloc compar therapeut categori across industri among drug current
clinic develop percentag oncology-focus clinic trial increas lastli small- mid-cap oncolog
stock group perform better non-oncolog stock recent year compani increasingli
initi coverag assum coverag biotech stock rate stock buy stock neutral
top pick arri key catalyst approach addit stock rate buy
bgne tsro adap stock rate neutral loxo
page analyst certif import disclosur
analysi show smidcap biotech group outperform teh time becom expens
last year said forward ev/ multipl still remain high think sever area opportun exist
investor context appli consist value-bas stock select rate framework coverag support
fundament analysi compani pipelin upcom catalyst convict level upside/downsid potenti street
expect sever commerci stage recommend coverag decreas significantli case
trade signific discount industri peer sever key catalyst horizon make compel valu stock
among emerg bioitech focu platform innov area includ precis oncolog
antibody-drug conjug adc immuno-oncolog
page analyst certif import disclosur
initi coverag
focu oncolog stock
page analyst certif import disclosur
tabl content
page analyst certif import disclosur
page analyst certif import disclosur
believ sector well posit longer term
bullish outlook
addit continu strong domest growth bio/pharmaceut therapeut market
expect emerg market china becom import addit sourc growth
innov view remain key driver stock expect suppli
new drug treatment modal remain strong new drug approv track
new high
level public compani acquisit investor expect
follow tax reform public compani transact announc ytd view
activ sector pois increas sever key drug franchis face loss patent
protect biosimilar launch loom balanc sheet potenti acquir remain strong
continu channel consolid cost manag program repres potenti
sourc uncertainti think innov compani remain well posit
context dynam
page analyst certif import disclosur
coverag focus oncolog therapeut categori repres
attract invest theme view
oncolog constitut second biggest therapeut market us grow
annual significantli faster drug
expect oncolog product demand continu increas driven unmet medic need
new drug remain high cancer mortal rate decreas increment
simultan oncology-focus compani investor benefit uniqu
dynam categori rel therapeut area includ acceler
biomark select strategi develop multi-ind drug develop
oncology-focus compani also oper one least generic pharmaceut market
us combin high degre fragment type cancer
could make categori potenti less expos commerci headwind
result believ oncolog seen larger amount resourc alloc compar
therapeut categori across industri among drug current clinic
develop percentag oncology-focus clinic trial increas
lastli small- mid-cap oncolog stock group perform better non-
oncolog stock recent year compani increasingli becom acquisit
page analyst certif import disclosur
initi coverag assum coverag stock
rate stock buy stock neutral
top pick arri key catalyst approach
addit stock rate buy bgne tsro adap
stock rate neutral loxo
analysi show smidcap biotech group outperform teh time
becom expens last year said forward ev/ multipl still remain
high think sever area opportun exist investor
appli consist value-bas stock select rate framework coverag
support fundament analysi compani pipelin upcom catalyst convict
level upside/downsid potenti
street expect sever commerci stage recommend coverag
decreas significantli case trade signific discount industri peer
sever key catalyst horizon make compel valu stock
among emerg focu platform innov area includ
precis oncolog antibody-drug conjug adc immuno-oncolog
page analyst certif import disclosur
page analyst certif import disclosur
themat coverag focus sever innov area think
favor posit within oncolog categori
wide valid class oral small molecule-bas drug tki believ re-emerg context precis
medicin includ biomark select sever pivot dataset regulatori decis expect
select next gener tki dramat increas sinc first agent enter market decad ago result
side-effect dramat decreas durabl respons significantli increas
genom data emerg recent year enabl develop precis medicin target specif genet
defin patient subset driver mutat biomarker-guid acceler drug develop typic lead earli
valid class antibody-bas agent ink cytotox payload gen agent success
believ categori re-emerg sever pivot dataset regulatori decis expect
four adc current approv us expect pivot clinic dataset disclos form agent us
regulatori decis least end
har patient immun system target cancer cell
expect enthusiasm cancer immunotherapi remain high given valid via agent car-t
approv well substanti market potenti believ investor select warrant given potenti logist
complex cellular therapi difficulti discern drug activ earli non-random trial immuno-oncolog
page analyst certif import disclosur
cover group commerci stage emerg pre-commerci
among commerci stage stock rate buy neutral
think street expect sever compani decreas significantli stock
trade multipl compress stock believ expect achiev
key pipelin catalyst horizon includ arri tsro
commerci stock rate buy includ bgne seen increas street
consensu think fundament strong busi pipelin major potenti catalyst
horizon high convict
stock rate neutral group think fundament strong
commerci franchis fulli valu view limit stock-mov catalyst horizon
chang street consensu revenu expect
page analyst certif import disclosur
coverag summari top pick base rate framework
addit stock rate buy
stock rate neutral
catalyst think could significantli impact stock
page analyst certif import disclosur
stock select framework base key fundament criteria
potenti pipelin longer term
much stock
near-term even ye could
confid level outcom
what account stock
upside/downsid vs target price
what upside/downsid best/worst
scenario
page analyst certif import disclosur
use consist valuat method across stock coverag
incorpor product-level dcf appropri loss exclus loe
consist assumpt loe generics/biosimilar entri
tier wacc assumpt discount rate cover stock
wacc commercial-stag stock
wacc pre-commerci stock posit clinic proof concept poc technolog
wacc pre-commerci stock without clinic poc technolog valid
termin year post-ip expir
page analyst certif import disclosur
arri buy best-in-class braf/mek inhibitor combo approv melanoma catalyst upsid
buy underappreci kit inhibitor address us oppti catalyst
buy high convict key binari event us oppti upsid
buy attract entri point fundament strong cabometyx biz key catalyst upsid
buy strong adcetri biz w/ limit competit impress line-up upsid
buy strong platform lead kit inhibitor stock key catalyst upsid
bgne buy uniqu posit take larg btk inhibitor market catalyst upsid
tsro buy neg sentiment expect low key catalyst upsid
buy neg sentiment parp expect low behind ovarian key catalyst upsid
adap buy earli stage cellular io platform focus solid tumor key poc data upsid
buy kol posit sacituzumab oppi launch fda approv catalyst upsid
buy neg sentiment low expect stock trade discount catalyst upsid
neutral strong platform pipelin lot price limit sourc upsid
neutral strong jakafi biz limit line-up meaning upsid driver
neutral lead gene therapi platform lot price limit visibl addl catalyst within year
loxo neutral impress trk ret data fairli valu limit n/t catalyst offer upsid
neutral intrigu nsclc data w/ sitravatinib current valuat lot price data earli
page analyst certif import disclosur
best-in class braf/mek inhibitor key catalyst approach arri own attract
platform special develop select tki either develop intern outlicens
believ stock current suffici reflect market potenti arri braftovi/
mektovi melanoma tki combin recent obtain us approv braf metastat patient
investor worri overal market opportun commerci launch melanoma base channel
check believ well recogn among potenti prescrib arri best-in-class
combin market translat well launch metastat market adjuv
melanoma repres signific sourc upsid longer term potenti larger market agent
base check
phase interim result beacon-crc phase trial mraftovi/mektovi repres
signific sourc potenti upsid stock market opportun braftovi/ mektovi braf
colorect cancer success probabl significantli higher us what current
reflect stock base estim arri first-in class limit competit
horizon braf patient alreadi identifi today part standard clinic practic wed expect
fast launch approv
lastli think arri royalti right license includ loxo azn
adequ reflect stock current trade ev/ significantli
industri averag
pt current share price street consensu pt consist
braf braf melanoma royalti license expect cash
year provid floor valuat beacon-crc fail
page analyst certif import disclosur
competit kit inhibitor address larg underserv market attract platform
special devt select tki much valu stock tie potenti lead
product candid kit inhibitor current phase clinic develop
believ stock current suffici reflect market potenti lead product candid
select kit inhibitor phase develop kit-driven gist gastrointestin stromal
tumor base analysi believ gist market opportun select kit inhibitor signific
us addit kit inhibitor also util system mastocytosi repres anoth
believ key near-term potenti catalyst repres major sourc upsid share
phase ib data system mastocytosi sm could potenti valid drug potenti
indic current stock phase result kit gist base
analysi high confid posit outcom event
frequent compar bpmc mcap avapritinib believ kit market
larg enough agent significantli potent current standard care ii
check physician indic agent like use sequenc non-overlap patient
subgroup succeed
pt current share price street consensu believ stock
could tripl ye best-cas scenario downsid bear-cas scenario
page analyst certif import disclosur
underappreci ovarian cancer agent late stage develop major binari event approach
imgn platform focus antibody-drug conjug adc much valu stock tie
fate lead product candid mirvetuximab fr-target current phase clinic
develop platinum-resist ovarian cancer
believ risk/reward own stock mirvetuximab phase result
favor base analysi data gener date believ probabl success
averag also like trial statist approach potenti enabl trial
succeed biomarker-high-onli patient overal studi miss
market opportun platinum-resist ovarian cancer underappreci base analysi
believ mirvetuximab market potenti us assum approv monotherapi
combin agent analysi also show potenti increas use parp inhibitor
ovarian cancer minim effect market potenti mirvetuximab
agent develop imgn collabor current stock three agent
partner current earli clinic develop hematolog cancer address valid
target aml bpdcn could potenti improv upon current develop agent phase
data updat expect repres sourc potenti upsid stock
pt current share price street consensu believ stock
could tripl ye best-cas scenario downsid bear-cas scenario
page analyst certif import disclosur
expect regulatori product approv coverag
page analyst certif import disclosur
catalyst roadmap coverag select
page analyst certif import disclosur
catalyst roadmap coverag select
advanc sm cancer
page analyst certif import disclosur
catalyst roadmap coverag select
page analyst certif import disclosur
page analyst certif import disclosur
overal environ industri remain favor
world-wide market therapeut grow new product
suppli driven continu innov
 potenti remain high larg biopharma compani face loss
patent exclus key product larg cash reserv hand
early-stag vc fund surpass level biotechnolog ipo
 fo return remain profit public investor provid capit
integr custom may diminish manufactur drug price power
potenti increas market custom engag expens
recent potenti chang polici medicar may limit access
certain therapeut potenti requir increas sg spend
page analyst certif import disclosur
 market therapeut larg expect
continu grow signific rate
us market expect reach billion usd
prescript drug spend growth expect accord statist
growth gener driven new drug launch growth demand exist brand growth price
partial off-set gener launch
page analyst certif import disclosur
innov key driver sector fda approv
steadili increas novel treatment modal enter market
new drug
pdufa date
drug approv
design
first-in-class fda
car-t gene tx vision
antisens oligonuc sma oncolyt viru
exclus indic expans already-approv drug nme new bla
page analyst certif import disclosur
abund capit may enabl emerg biopharmaceut
compani matur pipelin commerci drug
size vc fund round steadili grown
initi follow-on offer
time frame yield
posit return date investor
pharmaceut pharmaceut gener pharmaceut sector factset ipo
fo analysi includ aforement sector exclud postpon withdrawn offer
page analyst certif import disclosur
high cash reserv impend loss ip protect blockbust
agent may spur compani seek replenish pipelin
larg number drug lose exclus
 estim billion sale risk due
loss exclus patent
select portfolio compani risk
sale patent expir
 biosimilar erod innov sale quickli outsid us
evaluatepharma world preview outlook
xolair lost exclus biosimilar releas phase data
revlimid may face gener competit prior patent expir
settl biosimilar manufactur delay launch
suppli target asset
 activ
includ transact biotechnolog pharmaceut target exclud government-
own target compani mega-merg transact exclud mega-merg includ actavis-
analysi includ acquir abil financ deal debt compani share
page analyst certif import disclosur
recent largest acquisit target innov biopharmaceut
rare diseas oncolog asset
exclud acquisit compani signific over-the-count
consum health gener biosimilar anim health busi unit
page analyst certif import disclosur
on-going custom consolid cost manag program repres
may facilit implement
mostli pharmacy-benefit product
high white-bag volum
compani low overal budget
increas collect
impact hospit system
total
adopt icer metric
manufactur may need
high-cost drug competit area
demonstr cost-effect
patient
use co-pay accumul
use high deduct plan
specialti therapeut heavi
util patient out-of-pocket
harvard pilgrim-enbrel poorer patient outcom enbrel lead lower drug cost harvard pilgrim
bundl payment provid reimburs bundl payment base episod care
reimburs limit hospit reimburs hard limit paid back maryland
page analyst certif import disclosur
recent chang medicar allow higher degre payer restrict
medicar advantag grow
impact impend chang
upcom potenti chang medicar
part impact custom engag strategi
medicar
juli live
enrol medicar repres
insur live
upcom chang medicar
 step-therapi part drug indication-bas part
formulari cross-manag
implic part drug favor privat plan may benefit
payer implement similar restrict plan
potenti deeper rebat part drug especi
multipl indic tnf asthma etc defend share
competit part drug payer level
 part reimburs reduc asp asp
 transfer part drug administr part
implic addit pressur manufactur maintain
provid margin discount rebat may acceler
potenti increas drug rebat sg spend
payer market histor open-access custom
segment soon face addit margin pressur
page analyst certif import disclosur
increas biosimilar adopt could facilit
fda like tri acceler uptak
 fda releas draft guidanc interchang
granix zarxio
inflectra renflexi
 fda releas list non-exclus drug without gener
 biosimilar assign individu hcpc code part
 releas biosimilar action discuss
potenti tool make biosimilar develop effici
data share w/ foreign regul facilit biosimilar approv
reduc game regul prolong exclus
coordin ftc regard anti-competit behavior
go play regulatori whack-a-mol compani tri
unfairli delay derail entri biosimilar competitor
go wait decad robust biosimilar competit
page analyst certif import disclosur
expect oncolog remain favor posit among therapeut categori
increas number clinic trial
continu grow
growth driven
growth yoy gross price growth
within industri averag
compani shift
evalu oncolog product
util biomark screen
better identifi patient may
effect treat drug
data show trial util
biomarker-select higher
fda approv rate increas
drastic last year
nme submiss
increas approv driven
increas transpar
guidanc fda
preval label expans
due high unmet need among
fastest averag review time
file approv compar
therapeut class
half approv cancer
product approv
indic indic wide
breadth revenu stream lot
product
approv multi-
percentag product benefit
expedit review
indic quarter
approv indic
oncolog drug remain one
expens pharmaceut
treatment healthcar
remain within industri
averag potenti avoid
page analyst certif import disclosur
oncolog one largest class gross net sale
estimate us prescript drug sale tx class gross
estimate us prescript drug sale tx class net
page analyst certif import disclosur
unmet medic need oncolog expect remain high
cancer incid rate remain steadi cancer mortal rate declin slowli
new cancer case death per year
annual rate new cancer case
remain steadi sinc start
cancer year backdrop
grow age popul
cancer mortal rate decreas
slightli last decad suggest
high unmet medic need remain
despit improv prognos surviv rate recent year still cure avail
cancer patient oncolog remain underserv therapeut class
page analyst certif import disclosur
signific growth potenti oncolog drug china
expans public healthcar china
number new case
drug
drug
align global standard
popul price
lack capac backlog
barrier foreign-
increas access clinic trial
foreign-develop new drug
requir prior nda/maa
reform clinic trial manag
page analyst certif import disclosur
oncolog highli fragment therapeut class subtyp share
common characterist offer uniqu opportun drug develop
cancer fragment therapeut categori
label expans common within oncolog
cancer incid type
almost half approv oncolog drug expand
approv label least one follow-on indic
approv indic
result certain drug becom larg product
brain
oncolog fragment class often broken
major class cancer type
class subdivid
subclass cancer total
guggenheim secur llc estim data adapt ac represent naaccr data evaluatepharma
page analyst certif import disclosur
interpret clinic trial result anti-canc drug typic
unambigu biomark select improv success rate
use biomarker-bas select posit
affect success rate oncolog clinic trial
uniqu attribut make clinic trial oncolog
rel straight forward interpret
advanc biomark identif research
oncology- focus clinic trial use patient
screener result higher po clinic
checkpoint averag
single-ag recist respons
whether drug activ
high confid clinic result due
lack placebo effect tumor typic
dont shrink placebo alon
univers applic endpoint mani
phase ii phase ii phase
nda/bla
phase
higher success probabl
guggenheim secur llc estim data adapt clinic develop success rate
page analyst certif import disclosur
approv fastest regulatori timelin oncolog
fda approv rate doubl
last decad
oncolog product quickest time
file approv averag
fda taken guid role
pharmaceut compani product abl
success navig regul approv
addit oncolog product
major class fda approv
day nda file fda approv
page analyst certif import disclosur
industri averag price action low gener penetr make target
oncolog drug less vulner commerci headwind
oncolog gross price increas industri averag
estim histor price increas class
estim histor price increas class contd
overal oncolog degre generic target oncolog specif among estimate
price increas infer use iqvia sale prescript volum data
page analyst certif import disclosur
given opportun potenti oncolog remain major focu
oncolog seen larger amount alloc compar class
overal pipelin distribut across compani drug count
proport oncology-focus clinic trial increas substanti last year
clinic trial distribut drug type
guggenheim secur llc estim data adapt pharmaintellig fda
page analyst certif import disclosur
small mid-cap oncolog biotech stock perform better
recent year non-oncolog stock
perform calcul use observ percentag chang display year
stock weight base annual mean market cap index rebalanc weight averag basi calendar year
oncolog non-oncolog classif depend least compani portfolio plu pipelin
includ smidcap microcap stock
page analyst certif import disclosur
public oncolog biotech compani increasingli becom
 activ lower frequenc date
number deal
inclus criteria requir target biotechnolog pharmaceut industri public compani prior
transact list nyse addit transact requir take place later
page analyst certif import disclosur
biotech outperform market slower pace
follow correct
outperform slightli follow correct
annual perform calcul use observ percentag chang calendar year display
page analyst certif import disclosur
recent out-performance larg driven smidcap biotech
larg cap spec pharma recov
smidcap biotech outperform
larg cap under-perform
rel perform calcul use observ percentag chang compar baselin note stock weight base annual mean market cap index calcul weight averag
basi year classif criteria follow microcap biotech stock greater less market cap smid-cap stock market cap large-cap stock greater market cap
addit inclus criteria requir stock trade compani must human therapeut focu
page analyst certif import disclosur
smidcap biotech stock beat market
larg cap biotech stock continu under-perform
major smidcap biotech stock
under-perform follow year out-performance
proport smidcap biotech stock
proport larg cap biotech stock
under-perform market
under-perform market
smidcap biotech stock beat market
price chang
price chang ytd
large-cap biotech stock
under-perform market
price chang
price chang ytd
perform calcul use observ percentag chang compar mid cap smidcap larg cap
page analyst certif import disclosur
smidcap biotech multipl expand
still high
smidcap biotech mean ev/ multipl
still high
mean larg cap biotech multipl stabl
mean larg cap pharma multipl stabl
mean spec pharma multipl stabl
ev/ multipl calcul use histor enterpris valu consensu sale estim year forward respect date
compani includ requir least distinct analyst contribut consensu sale estim given calendar year
page analyst certif import disclosur
consensu revenu expect declin
consensu downward revis smidcap
mean chang consensu revenu
compani includ requir least distinct analyst contribut consensu
sale valu given year magnitud revis stock weight base
annual mean market cap index calcul weight averag basi year
page analyst certif import disclosur
compani profil report
page analyst certif import disclosur
page analyst certif import disclosur
arri one top pick believ arri attract
 platform special devt select tki
believ stock current suffici reflect market
potenti arri braftovi mektovi tki combin braf
melanoma recent obtain us approv addit
think po oppti braftovi/ mektovi braf
significantli higher what current reflect stock
posit phase interim result repres major potenti
catalyst stock addit quarterli earn lastli
think arri royalti stream license adequ
reflect stock trade ev/ pt
current share price significantli street
market opportun mektovi/braftovi
melanoma context evolv competit
success probabl acceler path
market mektovi/braftovi braf
sep eu approv mektovi/braftovi
us approv larotrectinib ntrk
phase braf colorect cancer
chart slide overal market perform
page analyst certif import disclosur
array lead commerci product mektivi braftovi tyrosine-kinas inhibitor tki recent us-approv
treatment patient metastat melanoma braf mutat europ drug combin commerci partner pierr
fabr regulatori decis expect end septemb japan arri partner
posit phase i/ii result also obtain line braf colorect cancer random phase trial combin
mektovi braftovi erbitux current enrol interim analysi expect repres import near-term
catalyst fore stock addit label expans opportun address collabor partner ipsen ipn roch
takeda
page analyst certif import disclosur
address broad opportun braf cancer
braftovi mektovi best-in-class brafi/meki agent
underappreci grow opportun braf
opportun braf huge arri first-to-
underappreci royalties/mileston out-licens
lead platform focus tki
bear late entri competit market
potenti shift standard care
braf melanoma small crowd market
still consider clinic regulatori risk braf
manag suffici maxim potenti
arri platform made poor bd decis
arri develop differenti platform
focus gener ultra-select tki arri
often critic out-licens best molecul loxo
casc etc think platform still hold signific valu
product engin arri continu conduct intern
revenu forecast significantli street
consensu bullish view driven posit feedback
receiv physician regard braftivi/mektovi potenti
braf melanoma well analysi braf
market suggest sale potenti
braftivi/mektovi also gener detail
forecast royalti deriv arri partner product
loxo azn suggest street underestim
potenti
high convict pipelin high convict
success probabl braftovi mektovi braf
po well late-stag partner program
near-term data event could serv potenti
catalyst stock
signific valuat upsid potenti pt
current share price peer
downsid bull/bear case
page analyst certif import disclosur
per dcf
braftovi mektivi growth braf met melanoma
po beacon- phase braf
po selumetinib azn
po larotrectinib ntrk gene fusion cancer
po trki-resist patient
po ret tumor
beacon selumetinib
trial failur
 regulatori commerci setback braftovi mektovi
potenti emerg new competitor
failur out-licens product
page analyst certif import disclosur
page analyst certif import disclosur
page analyst certif import disclosur
arri mm fy end june mileston collabor product sale p/w- royalti p/w- reimburs total cogs- sg total oper oper incom interest interest total incom tax expense- net incom dilut ep per share outstand arri bs cf arri stock select rank
posit least well posit rel peer
high convict success probabl braftovi mektovi
braf well late-stag partner program
near-term data event could serv potenti catalyst stock
collabor focu evalu mektovi
combin cpi although po modest view
futur
revenu forecast significantli street consensu
opportun braf metastat melanoma includ adjuv
forecast pos-adjust us peak sale braf
royalti estim arri partner peak
braftovi mektovi approv europ sep po
larotrectinib approv trk cancer po
beacon top-lin interim data braf po
data updat ret tumor
pt current share price well
downsid bull/bear case
compani current cashflow-neg
expect arri becom oper cashflow-posit
current asset cash
convert note loan
page analyst certif import disclosur
overview
royalti
array pipelin
product potenti
anticip
braftovi mektovi
perform melanoma
evalu
market understand
may array expect
potenti futur
scenario impact
compani valuat
page analyst certif import disclosur
arri best-in-class braf mek inhibitor combin licens
tki pipelin main valu driver stock
phase
tumor loxo
tumor azn
cancer
tumor aslan
loxo
tumor loxo
page analyst certif import disclosur
price target reflect braftovi/mektovi potenti braf
melanoma braf po potenti royalti incom
believ arri current under-valued
royalti mileston out-licens product
royalti astrazeneca ww selumetinib sale
royalti loxo bayer ww trk inhibitor sale
royalti loxo ret inhibitor sale
royalti tucatinib sale
royalti aslan ww varlitinib sale
braftovi mektovi melanoma approv
tier royalti row sale
braftovi mektovi on-going ph w/ initi data
posit phase ii safeti lead-in data vs standard
larg market opportun limit competit
us commerci right royalti row sale
aslan varlitinib royalti includ model
page analyst certif import disclosur
investor controversi view
size braf melanoma opportun
bear argument immunotherapi consider share braf-mut melanoma compet braf mek combin
mek/braf market crowd
bull argument braf mek agent consist revenu growth despit braftovi mektovi best-in-
class captur share incidence-driven market
guggenheim view array combin expect rapidli gain market share given best-in-class attribut lack side
effect commonli associ compet braf mek combin pyrexia skin rash etc base discuss
physician adjuv braf melanoma repres larg sourc long-term upsid class base check
kol
probabl success magnitud opportun braf
bear argument arri phase dataset still small data form competitor look less strike recent chang phase
bull argument phase ii data gener unpreced arri mek/brafi clearli differenti
tki current soc
guggenheim view array phase safeti lead-in data indic high probabl success beacon trial
potenti chang current standard care braf-mut patient
valu arri potenti royalti stream mileston payment
bear argument product yet de-risk failur high-risk program selumetinib possibl
bull argument data gener far highli promis potenti royalti stream stock
guggenheim view believ array out-licens product strateg well posit within respect market
segment demonstr consider clinic benefit respect diseas expect array obtain
signific royalti revenu move forward although due complex market think like underestim
street
page analyst certif import disclosur
current standard care braf-mut melanoma includ sequenti
treatment braf/mek immune-checkpoint inhibitor
melanoma expert expect tki io agent use manag braf patient
standard
base recent kol interview
opdivo yervoy
potenti long-term growth opportun
roughli patient expect
braf mek
whichev use prior
array combin view
best-in-class physician
expect arri captur market
share nv
checkpoint
use patient
toler tafinlar/mekinist well
page analyst certif import disclosur
kol believ braf mek inhibitor remain cornerston braf-
mutant melanoma therapi despit presenc immunotherapi
im prescript volum braf mek inhibitor
temporari decreas rx volum
potenti due expans
 braf melanoma
quarterli growth vs quarter previou year
page analyst certif import disclosur
best-in-class statu arri braftovi-mektovi combin
clinic overview braftovi mektovi vs braf mek inhibitor
teae
encorafenib binimetinib dont certain
toxic brak mek inhibitor
better surviv clearli best class
novarti drug issu pyrexia
roch drug skin toxic array
combo better toxic
outcom vs
consider lower incid pyrexia
skin toxic favor ae profil
potenti due short mektovi half-lif
page analyst certif import disclosur
braftovi mektovi well posit competit landscap emerg
therapi melanoma
inhibitor trial cancel
late-phas all-com directli
compet braf mek inhibitor
refractori set
clinicaltri gov indic primari complet also state trial yet recruit
page analyst certif import disclosur
estim peak sale potenti braftovi mektovi braf
kol optimist uptak braf melanoma
 braftovi mektovi prescrib combin
 checkpoint inhibitor split market braf mek inhibitor
 braftovi mektovi captur braf/mek inhibitor treat
metastat patient peak
 use adjuv therapi
braf mek inhibitor achiev
net us sale midst competit
prior expans beyond metastat melanoma
page analyst certif import disclosur
braftovi mektovi well posit view initi entri
braf-mut follow potenti label expans front-lin tx
standard agent
potenti label expans opportun front-lin
braftovi mektovi expect rapidli captur
major market accord kol given poor
prognosi lack option
msi-h keytruda
stivarga unlik pose competit threat
array given poor clinic efficaci
fda approv back nccn
page analyst certif import disclosur
initi result safeti lead-in patient suggest potenti
anoth best-in-class combin within
clinic overview braftovi mektovi vs therapi
patient
associ poorer outcom
best-in-class orr
profil rel
tafinlar vectibix arm mo month
os data matur month median os reach
nccn recommend fda approv
page analyst certif import disclosur
interim phase result braf expect key
potenti catalyst stock opinion
enrol beacon trial
continu strong anticip full
enrol around end year
interim updat includ orr
durabl respons appropriately-pow
statist analys three arm
page analyst certif import disclosur
braf reflect us opportun braftovi/mektovi
base estim
median month os braf statu
lower benchmark success
patient
therapi
potenti market opportun
billion unit state
calgb swog subgroup analysi braf-mut patient
receiv avastin erbitux folfiri egfr therapi gener
ineffect braf-mut
assum patient re-treat progress
assum braf patient concomit msi-
 prescrib checkpoint inhibitor therapi
page analyst certif import disclosur
forecast potenti peak annual braftovi mektovi us net sale
bn includ expans
braftovi mektovi prescrib combin out-class
competitor except cpi msi-h
annual net price increas start month
page analyst certif import disclosur
array entitl signific royalti out-licens product
candid forecast peak pos-adjust
divers mix incom royalti stream
 royalti forecast out-licens product
 tier royalti pierr fabr eu sale
 tier royalti ono jpn sale
 double-digit royalti world-wide tucatinib sale
 royalti world-wide selumetinib sale
 mid-singl digit royalti world-wide trk ret
inhibitor loxo oncolog ret mileston credit
royalti
pierr fabr
ono pharmaceut
ret inhibitor trk inhibitor
assum probabl success
braftovi mektovi
tucatinib breast
selumetinib tumor
page analyst certif import disclosur
favor upside/downsid scenario rel current share price
 upsid approv out-licens product
 braftovi mektovi approv front-lin
 trial failur braftovi mektovi obtain indic
 downsid beacon failur poor melanoma uptak
melanoma penetr reduc annual peak sale
page analyst certif import disclosur
braftovi mektovi best-in-class braf mek inhibitor combin patient braf-
improv os vs current market leader tafinlar mekinist vs month
vs month respect melanoma trial random vs zelboraf
beacon safeti lead-in data suggest doubl standard-of-car recist orr
improv os braf mutant popul
ii arri elig royalti mileston set highli promis out-licens product
forecast peak annual royalti ex-u ww sale braftovi mektovi
selumetinib tucatinib larotrectinib
risk/reward compel view own stock
current price target share suggest signific upsid current share price
bearish scenario current reflect stock
arri could worth much share upsid bull-cas scenario
recommend buy rate arri given best-in-class product melanoma de-risk pipelin highli
promis market potenti colorect cancer combin royalti stream innov program
page analyst certif import disclosur
page analyst certif import disclosur
one top pick believ attract
 platform special develop tki
believ stock current suffici reflect market
potenti lead product candid select kit
inhibitor phase develop gist believ key near-
term potenti catalyst repres major sourc upsid phase
ib data system mastocytosi sm repres larg
opportun current stock phase
result gist comparison bpmc avapritinib
like ultim believ kit market larg enough
agent estim pt
current share price significantli street consensu
competit posit gist
probability-of-success system
probability-of-success gist vs
expans cohort system mastocytosi
phase trial gist
intrigu phase trial gist
chart slide overal market perform
page analyst certif import disclosur
emerg compani focus develop differenti kinas inhibitor tki lead
product candid spectrum-select kit inhibitor undergo clinic develop kit gist advanc system
mastocytosi asm well kit-driven solid tumor first pivot trial invictu expect read-out rebastinib
inhibitor immuno-kinas singl agent phase studi cml/aml complet investigator-sponsor trial ist
chemotherapi on-going plan initi combin studi chemotherapi cpi select inhibitor
current phase dose-escal studi
advanc sm cancer
page analyst certif import disclosur
bull under-valued stock high sale
potenti kit-driven cancer
partial de-risk lead product candid
consider sale potenti larg kit-driven cancer
potenti catalyst next month suggest
signific upsid current level bull-cas scenario
valu pipelin agent stock free upsid
bear one-product stori expos
clinic risk yet fulli de-risk particular
system mastocytosi
competit may ultim emerg winner
kit market ahead
one product stori limit valu pipelin beyond dcc-
develop differenti platform
focus gener tki potenti less
sensit resist mechan believ dcph
platform hold promis potenti overcom major
drawback tki wide valid class target anti-
revenu forecast significantli street
consensu bullish view driven posit feedback
receiv physician regard potenti kit
inhibitor gener well bullish
potenti particular gist sm repres
major sourc upsid forecast think kit market
big enough two agent competitor see
upsid given current valuat
high convict high convict
success probabl gist believ drug
favor posit ahead gist competit
posit sm remain open question repres
sourc upsid potenti potenti catalyst
approach updat gist data gist
phase sm phase ib data dont valu dcph
valuat upsid pt current share
price street consensu
downsid bull/bear case
page analyst certif import disclosur
per dcf
 regulatori commerci setback
potenti emerg new competitor
dilut financ beyond assum
po gist invictu
po gist intrigu
po asm
valu indolent/smold sm
po gist vs placebo
posit phase updat gist
posit ph data asm posit
compar superior vs avapritinib
pursuit indolent/smold sm
result potenti lower market captur
gist lower po gist
zero valu asm i/ssm
page analyst certif import disclosur
page analyst certif import disclosur
page analyst certif import disclosur
incom statement sales- collabor revenue- royalties- total revenues- cogs- total cost oper incom interest incom interest loss extinguish debt- incom incom tax- net incom dilut ep per share outstand share outstand bs cf stock select rank
posit least well posit rel peer
investor focu predominantli spectrum-select kit inhibitor dcc-
phase trial gist well earlier-phas
high convict success probabl gist
indic given promis initi phase data variou line therapi
early-stag pipelin includ rebastinib inhibitor
inhibitor phase
discoveri stage tki focu cancer metabol immun kinas
revenu forecast street consensu
forecast probability-adjust us eu peak sale dcc-
valu dcph pipelin beyond repres upsid
estim
data updat could re-posit
rel competitor
phase updat kit gist
phase ib data asm
phase data gist
pt current share price peer
downsid bull/bear case
compani current cashflow-neg
addit financ necessari achiev break-even
page analyst certif import disclosur
current soc
forecast impact
current standard
care investor
kit inhibitor data
compar
potenti revenu
impact
page analyst certif import disclosur
sequenti treatment multi-kinas inhibitor current standard
care kit/pdgfra-driven cancer
target therapi kit-driven malign
gist subtyp
therapi
standard
sm subtyp
therapi
standard
lack approv
drug unmet need
page analyst certif import disclosur
market potenti new select kit inhibitor larg
kit pdgfr driven tumor repres potenti sale opportun base
therapi
estim time
incid advsm gist given malign diseas preval model ism ssm given chronic diseas
base publicly-avail progression-fre surviv data novel current standard care agent
potenti reduc drug price long-term util drug low dose
page analyst certif import disclosur
 develop select kit inhibitor
constitut major current valu upsid potenti
advanc program sm gist
focus date predominantli gist
valuat distribut kit inhibitor
base assumpt
see upsid potenti
context overal kit market opportun
although believ risk/reward
kit inhibitor account
major
valu view
potenti kit inhibitor
ret fusion mutant solid tumor
page analyst certif import disclosur
new kit inhibitor exhibit tighter select bind disease-
drive mutat target current approv multi-kinas inhibitor
kinom map kit-specif
inhibit disease-driv
inhibit disease-driv
specif bind kit
stronger inhibit disease-
potenti clinic efficaci
laid groundwork futur
clinic studi human
page analyst certif import disclosur
preclin data suggest select mutant
inhibitor design spectrum-select
sm mostli driven kit gist
much heterogen mutat profil
consider tighter bind
kit pdgfr
broader inhibit
adopt modifi preclin poster
data shown kit exon secondari resist mutat
page analyst certif import disclosur
phase clinic data releas date suggest superior
currently-approv benchmark therapi
orr recist
orr recist
orr recist
orr recist
iwg
ae profil
page analyst certif import disclosur
trial overview believ succeed differ
area kit inhibitor market
page analyst certif import disclosur
trial plan announc
near-term potenti stock catalyst includ clinic trial updat
may inform rel competit
timelin near-term potenti catalyst
data updat
nda file acceler approv
phase result gist
phase advsm
phase ssm vs
phase gist result
prior regimen
phase gist vs
phase expans result advsm
page analyst certif import disclosur
base kol feedback assum split
kit market although upcom data disclosur may affect pictur
probability-adjust sale forecast diseas base data present far sm gist
aggress pursu develop
sm given pathfind pioneer trial
focus gist
gist may key high risk-reward market given
need novel agent beat sutent larger
popul potenti longer treatment durat
page analyst certif import disclosur
limit downsid underappreci investor
posit gist updat captur half kit-driven gist market maintain lead
avapritinib po increas gist vs indic launch time remain
posit advsm updat captur half overal sm market po advsm increas
po ism ssm increas launch time remain
page analyst certif import disclosur
current unmet need signific market opportun patient system mastocytosi gastrointestin
advsm gist market potenti billion dollar opportun
therapi beyond gleevec rydapt larg ineffect non-exist
ii data gener date suggest may effect inhibit select kit mutat deciphera
product develop inhibit broader rang kit mutat
may explain high degre activ pdgfr gist asm predominantli
driven kit mutat
activ kit gist remark compar soc particular sinc kit-gist
much heterogen kit mutat profil asm
competit dynam continu evolv
undergon develop sm may launch first pdgfr gist well
current lead indic expans key gist popul
upcom near-term data readout
phase data avapritinib activ kit gist
phase data asm
iv valuat potenti scenario suggest compani consider upsid potenti howev
believ risk-reward own favor context current valuat stock potenti
page analyst certif import disclosur
page analyst certif import disclosur
one top pick platform focus
antibody-drug conjug adc buy-thesi base
factor believ lead product mirvetuximab higher po
platinum-resist ovarian cancer proc expect
market opportun proc significantli larger anticip
investor estim us alon valu
current stock earli clinic stage asset
partner address valid target hem
cancer sourc signific upsid view mirvetuximab
phase result expect combin data
keytruda could preced catalyst pt
current share price significantli peer
success probabl forward-i phase trial
lead asset mirvetuximab platinum-resist
size market opportun mirvetuximab
platinum-resist sensit ovarian cancer
manag abil success diversifi
pipelin without overextend balanc sheet
ii trial keytruda combin w/ proc
phase result aml
phase result hem
phase result forward-i trial proc
chart slide overal market perform
page analyst certif import disclosur
lead product candid mirvetuximab soravtansin antibody-drug conjug target folate-receptor alpha fr
import upcom catalyst stock phase forward-i clinic trial fr-posit platinum-resist ovarian cancer
patient proc fulli enrol expect releas top-lin result
also evalu mirvetuximab combin agent includ avastin carboplatin keytruda multi-arm
phase ii trial forward-ii potenti justifi futur develop mirvetuximab much broader patient popul ovarian cancer
updat result keytruda combin arm present upcom esmo confer
addit adc develop hematolog cancer part collabor option agreement
target respect two clinic valid target aml hematolog cancer
agent phase dose-escal trial receiv support world-wid opt-in right agent
page analyst certif import disclosur
underappreci near-term catalyst
signific near-term potenti catalyst above-averag
magnitud market oppti mirvetuximab proc
label extens opportun underestim street
partnership aml focu stock
bear riski stori given histori failur
record adc difficult indic
moder market size proc
valuat floor lead program fail
aml competit difficult categori
own one valid platform
new leadership focu resourc highest valu
asset divest much proprietari partner
pipelin strategi paid view
revenu forecast significantli street
consensu bullish view driven posit feedback
receiv physician regard potenti
mirvetuximab proc either singl agent combin
agent believ drug address
market oppti us proc alon account
potenti label expans oppti psoc cancer
high convict pipelin high convict
success probabl mirvetuximab proc phase
result expect key binari event also
believ could differenti
profil exist agent valid respect
target hematolog cancer
collabor maxim potenti
signific valuat upsid potenti pt
current share price peer
downsid bull/bear case
page analyst certif import disclosur
gs assumpt upside/downsid scenario
per dcf
po forward-i trial recurr proc
po mirvetuximab recurr proc combin
avastin keytruda
mirvetuximab valu platinum-sensit oc
po aml
phase success proc forward-i
support phase data aml
phase failur proc forward-i
valu mirvetuximab combin oc
limit impact aml data
potenti emerg new competitor
lower product sale expect
dilut financ beyond assum
page analyst certif import disclosur
page analyst certif import disclosur
page analyst certif import disclosur
incom statement mileston royalti revenu clinic materi product sales- product royalti revenue- total cogs- total oper oper incom total expens net incom incom tax expens benefit net incom dilut share outstand bs cf stock select rank
posit least well posit rel peer
investor focu predominantli mirvetuximab late stage
clinic develop high convict success probabl
agent ovarian cancer singl agent combin
agent
imgn partnership around two earli clinic develop aml
asset current underappreci investor offer pipelin
diversif mid term
revenu forecast significantli street consensu
believ mirvetuximab address commerci opportun
us alon approv own ww right product
could potenti add anoth global sale go
valid target aml expect commerci
opt-in right agent
potenti de-risk mirvetuximab proc po
visibl mirvetuximab potenti combin keytruda
avastin/carboplatin po
visibl potenti aml po
pt current share price peer
downsid bull/bear case
runway base current cash balanc
addit financ need achiev cash-flow break-even
addit debt capac potl mirvetuximab approv
page analyst certif import disclosur
overview
immunogen
pipelin product
market
opportun
probabl
success on-going
label potenti
expans opportun
mirvetuximab proc
potenti futur
scenario impact
imgn valuat
page analyst certif import disclosur
mirvetuximab imgn main valu driver current phase
develop platinum-resist ovarian cancer
phase
malign
page analyst certif import disclosur
current price target primarili base potenti lead
pt suggest signific upsid current
aml partner
first-in-class ign payload alkyl
crosslink dna
tier royalti ww sale low-doubl digit
mirvetuximab proc singl agent phase ii
initi data on-going trial show superior efficaci vs
standard care
larg market opportun limit competit
page analyst certif import disclosur
investor controversi view
size platinum-resist ovarian cancer opportun
bear argument major ovarian cancer oc patient diagnos platinum-sensit diseas thu leav rel
small market share drug target platinum-resist ovarian cancer proc
bull argument limit treatment option proc patient high unmet medic need
guggenheim view ovarian cancer patient initi respond platinum-bas treatment eventu develop resist give
rise larg pool proc
bear argument newli approv agent bevacizumab parp inhibitor etc mainten set platinum-sensit
ovarian cancer psoc therapi shrink psoc pool delay develop platinum resist
bull argument treatment proc remain larg unaffect
guggenheim view base literatur review data analysi believ bevacizumab parp inhibitor limit
impact platinum-sensit oc patient
probabl success forward phase trial
bear argument design phase trial absenc random phase studi repres consider risk
bull argument data earli stage trial compar favor histor data
guggenheim view high convict success probabl mirvetuximab singl agent combin
agent base data present date acknowledg binari risk
page analyst certif import disclosur
current standard care platinum-resist ovarian cancer includ
limit option
standard
mirvetuximab bev pembro
mirvetuximab bev pembro
mirvetuximab bev pembro
pegyl liposom doxorubicin weekli paclitaxel topotecan
page analyst certif import disclosur
mirvetuximab evalu monotherapi combin
treatment proc phase data expect
timelin trial psoc
design mirvetuximab vs paclitaxel topotecan
primari endpoint patient fr high
page analyst certif import disclosur
phase i/ii data gener date compar favor histor data
clinic overview mirvetuximab vs soc clinic trial agent
teae grade
pegyl liposom doxorubicin weekli paclitaxel topotecan
advanc ovarian cancer patient includ plat-sensit -resist
fifteen patient discontinu bevacizumab and/or mirvetuximab soravtansin due treatment-rel frequent thrombocytopenia
one bevacizumab-rel death intestin perfor occur studi
page analyst certif import disclosur
shot goal forward phase trial design nest
end-point analysi depend fr biomark express
patient random two arm
power detect hr fr high group
power random patient
study-wis level
prior line therapi ovarian cancer
fr med/high fr high
success
one
guggenheim secur llc estim journal clinic oncolog
page analyst certif import disclosur
although major patient diagnos platinum-sensit oc
patient eventu becom platinum-resist sever line treatment
patient pool mirv
patient prior treatment
number refer new patients/year
page analyst certif import disclosur
increas use new agent psoc modest impact
market opportun mirvetuximab platinum-resist diseas
split current mainten therapi psoc
modest impact newli approv drug psoc
impact new agent psoc proc patient pool
new agent approv mainten set
psoc keep patient respond chemo
longer time potenti shrink earlier line
bev mainten
bev mainten
parpi mainten
parpi mainten
like case
parpi mainten
number patient
platinum sensit oc patient treatment plat-sensit pt
 chemo
bev mainten mainten
parpi mainten
parpi mainten like hypothet max impact
page analyst certif import disclosur
base assumpt believ mirvetuximab could potenti
address sale opportun us
therapi mo
potenti market opportun
billion us
cannib
assum probabl success
 mirvetuximab monotherapi proc
 mirvetuximab combo therapi proc
assum patient re-treat progress
page analyst certif import disclosur
potenti opportun mirvetuximab platinum-sensit ovarian
cancer repres potenti sourc upsid estim
standard
earlier line
page analyst certif import disclosur
mirvetuximab time line platinum-sensit landscap
timelin competitor trial primari
page analyst certif import disclosur
interest earli mirvetuximab data present platinum-sensit oc
clinic overview mirvetuximab vs soc clinic trial agent
teae grade
chemo
effect top
chemo
mostli
effect
pt averag time pt receiv last chemo mainten control control group
brca pt averag time pt receiv last chemo mainten total
page analyst certif import disclosur
